Author

N. Proost

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

M. van de Ven· 3 shared A. Berninger· 1 shared A. Bosma· 1 shared A. Gasparini· 1 shared A. H. W. Essing· 1 shared A. Kersbergen· 1 shared A. Kucukosmanoglu· 1 shared A. Mulero-Sanchez· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. van de Ven

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma

K. J. Ciecielski, A. Mulero-Sanchez, A. Berninger, L. R. Canas, A. Bosma, K. Gorgulu, N. Wu, K. N. Diakopoulos, E. Kaya-Aksoy, D. A. Ruess, D. Kabacaoglu, F. Schmidt, L. Heinemann, Y. Fan, B. Thijssen, , S. Mainardi

This paper investigates the combination of SHP2 and ERK inhibition as a treatment for KRAS-driven pancreatic ductal adenocarcinoma, showing synergistic anticancer effects and tumor regression in mouse models.

bioRxiv · Dec 14, 2021 · PreprintCancer Biology

Loss of p16INK4a in neuroblastoma cells induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors

N. A. Schubert, S. R. van Hooff, L. Schild, K. Ober, M. Hortensius, K. van den Handel, A. H. W. Essing, B. Koopmans, M. Boeije, N. Proost, M. van de Ven, S. Jansky, S. A. Stainczyk, U. H. Toprak, F. Westermann, , M. L. van den Boogaard

bioRxiv · Oct 27, 2021 · PreprintCancer Biology

Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors

M. Barazas, A. Gasparini, Y. Huang, A. Kucukosmanoglu, S. Annunziato, P. Bouwman, W. Sol, A. Kersbergen, N. Proost, M. van de Ven, J. Jonkers, G. Borst, S. Rottenberg

This study identifies radiotherapy as a therapeutic target for BRCA1-deficient tumors that have developed resistance to PARP inhibitors through 53BP1 pathway inactivation.

bioRxiv · Jul 17, 2018Cancer Biology